Evaluation of the therapeutic response to In-111-DTPA octreotide-based targeted therapy in liver metastatic neuroendocrine tumors according to CT/MRI/US findings.
Thirteen (13) patients with liver neuroendocrine carcinomas metastases, positive for somatostatin receptors, confirmed by scintigraphy were infused with 4070-7030 MBq per session of In-111-octreotide after selective hepatic catheterization, exploiting the catastrophic activity of Indium Auger and Internal Conversion electron emission on cell DNA. Evaluation of the treatment was assessed by ultrasonography (US) as well as by computed tomography and/or magnetic resonance imaging scans. US appears to be the imaging procedure of choice because the examination is sensitive for evaluating lesions' edema and cystic components, provides precise measurement of tumor size, and is inexpensive. Degeneration US signs were classified in stage I (an echolucent rim in the periphery of the lesion), stage IIa (lesion with large cystic spaces), stage IIb (tiny cystic spaces) and stage III (absorption of the cystic component or stable cystic remnants).